levoleucovorin and Carcinoma--Lewis-Lung

We evaluated the antitumor effect of combined therapy with tegafur/uracil (UFT) plus leucovorin (LV) (UFT/LV) and protein-bound polysaccharide, PSK, in three mouse models of transplantable tumors. UFT/LV showed antitumor effect against Meth A sarcoma, and the antitumor effect was enhanced when PSK given concomitantly. UFT/LV showed antitumor effect to Lewis lung carcinoma and PSK alone also showed antitumor effect at high dose, but a combination of UFT/LV and PSK resulted in no enhanced antitumor effect. Colon 26 carcinoma was weakly responsive to UFT/LV, and no enhancement of antitumor effect was found even PSK was used in combination. In conclusion, while the effect of PSK varies depending on tumor, combined use of UFT/LV and PSK may be expected to augment the antitumor effect.

Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Colonic Neoplasms; Disease Models, Animal; Drug Therapy, Combination; Female; Leucovorin; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Proteoglycans; Sarcoma; Tegafur; Uracil; Xenograft Model Antitumor Assays